Friends! In this video, I'm going to do a Hims stock analysis
1 extracted signal · 1 resolved · 0 still active
The Patient Investor04 Sept 2025, 20:59 UTC
AI-generated source summary
The analysis focuses on Hims & Hers Health (HIMS). The stock is currently at $44.46, down approximately 30% over the previous month but up 76% year-to-date. The presenter notes HIMS is trading at roughly three times sales with approximately 54% sales growth and 80% gross margins. A potential lawsuit and related negative media could be ending. The pundit suggests HIMS can obtain a rerating to 6-10 times sales. Expansion into Europe and Canada are also noted. The target price is inferred to be 67.42 with the failure bound set around $40.00. The prediction timeframe is approximately 5 years and the current and predicted trend is that it will become bullish soon.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.